Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-05-15
2007-05-15
Yu, Misook (Department: 1642)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C530S300000, C536S023100, C435S069100, C435S070100, C435S320100
Reexamination Certificate
active
09786867
ABSTRACT:
A DNA sequence coding for oncofetal ferritin 1 (OFF1) as well as an amino acid sequence encoded by the DNA sequence. Pharmaceutical compositions may be prepared comprising the above-sequences for treating various diseases, for facilitating transplantations and for treating pathological pregnancies.
REFERENCES:
patent: 4882270 (1989-11-01), Moroz
patent: 4954434 (1990-09-01), Moroz
patent: 5120640 (1992-06-01), Moroz et al.
patent: 5283177 (1994-02-01), Moroz et al.
patent: 5571678 (1996-11-01), Moroz et al.
patent: 0 426 458 (1991-05-01), None
patent: WO 89/09936 (1989-10-01), None
Moroz et al., (J. Biol. Chem., vol. 277, Issue 15, 12901-12905, Apr. 12, 2002).
Forre et al (2000, Scand J Rheumatol vol. 29, pp. 73-84).
Friedmann (Scientific American, Jun. 1997, pp. 96-101).
Verma and Somia (1997, Nature, vol. 389, pp. 239-242).
Rubanyi (2001, Molecular Aspects of Medicine 22, pp. 113-142).
Abstract—XP-002131126—Anderson et al. “Sequence and organization of the human mitochondrial genome”,Nature, 290:457-465 (1981).
Abstract—XP-002131125—ZH Life Technology Kenkyusho “Human monocyte growth factor”, p. 1, line 19-25 (1995).
Abstract of Japan—Manabu “Recombined growth factor for human monocyte, and DNA sequence coding the same” (1995).
XP-000877132—Fisch et al., “Placental isoferritin as a marker of early abortion in pregnancies induced byin vitrofertilization”,Piacenta, 17:247-251 (1996).
XP-000876880—Rosen “Placental isoferritin-associated p43 in pregnancy and breast cancer minireview”,Neoplasma, 43:357-362 (1996).
XP-000877134—“Placental isoferritin: a new biomarker from conception to delivery”,British Journal of Obstetrics and Gynaecology, 103:301-305 (1996).
XP-000876882—Yaniv et al., “p43, a new placental isoferritin subunit, is a growth factor for granulocyte-monocyte progenitor cells”, p. 272.
XP-002131123—Moroz et al., “T-cell mitogenesis stimulates the synthesis of a mRNA species coding for a 43-kDa peptide reactive with CM-H-9, a monoclonal antibody specific for placental isoferritin”,Proc. Natl. Acad. Sci. USA, 86:3282-3285 (1989).
XP-000876978—Garty et al., “High serum levels of placental isoferritin p43 component in down syndrome”,Human Sciences Press, Inc., 39-41 (1998).
XP-000876881—Higgy et al., “Differential expression of human ferritin H chain gene in immortal human breast epithelial MCF-10F cells”,Molecular Carcinogenesis, 20:332-339 (1997).
XP-000876843—Boyd et al., “Structural and functional relationships of human ferritin H and L chains deduced from cDNA clones”,The Journal of Biological Chemistry, 260:11755-11761 (1985).
Ferguson et al., “Comparison of a novel assay for breast cancer mucin to CA15-3 and carcinoembryonic antigen”,Journal of Clinical Oncology, 10:1057-1065 (1992).
Werner et al., “Clinical utility and validation of emerging biochemical markers for mammary adenocarcinoma”,Clinical Chemistry, 39:11(B)2386-2396 (1993).
Jones et al., “An □mmunoradiometric assay for the acidic ferritin of human heart: application to human tissues, cells and serum”,Clinica Chimica Acta., 85:81-88 (1978).
Giannoulis et al., “Diagnostic value of serum ferritin in primary hepatocellular carcinoma”,Digestion, 30:236-241 (1984).
Fine et al., “Ferritinaemia in cancer”,Nature, 265:755-756 (1977).
Covell et al., “Isoferritins in plasma”, 49-65 (1984).
Drysdale “Ferritin phenotypes: structure and metabolism”, 41-67.
Brown et al., “Characterization and localization of human placental ferritin”, 182:763-769 (1979).
Parhami-Seren et al., “A unique subunit structure of human placenta ferritin identified by the use of monoclonal antibodies”,G. I. Pat. Clin., 1:17-23 (1986).
Arosio et al., “On ferritin heterogeneity further evidence for heteropolymers”,The Journal of biological Chemistry, 253:4451-4458 (1978).
Drysdale et al., “Carcinofetal human isoferritins in placenta and HeLa cells”,Cancer Research, 34:3352-3354 (1974).
Matzner et al., “Serum ferritin in hematologic malignancies”,American Journal of Hematology, 9:13-22 (1980).
Bezwoda et al., “Serum ferritin and Hodgkin's disease”,Scand J Haematol., 35:505-510 (1985).
Cragg et al., “Isoferritins in acute leukaemia”,Br. J. Cancer, 35:635-642 (1977).
Halliday et al., “Isoferritin composition of tissues and serum in human cancer”,Cancer Research, 36:4486-4490 (1976).
Jones et al., “Serum ferritin in patients with cancer: determinatin with antibodies to HeLa cell and spleen ferritin”,Clinica Chimica Acta, 106:203-214 (1980).
Daly et al., “Comparison of a novel assay for breast cancer mucin to CA15-3 and carcinoembryonic antigen”,Journal of Clinical Oncology, 10:1057-1065 (1992).
Demers et al., “CA-549: A new tumor marker for patients with advanced breast cancer”,Journal of Clinical Laboratory Analysis, 2:168-173 (1988).
Dnistrian et al., “Evaluation of CA M26, CA M29, CA 15-3 and CEA and circulating tumor markers in breast cancer patients”,Tumor Biol., 12:82-90 (1991).
Browdy and Neimark PLLC
Gardino Investment N.V.
Yu Misook
LandOfFree
DNA sequence encoding oncofetal ferritin protein does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with DNA sequence encoding oncofetal ferritin protein, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and DNA sequence encoding oncofetal ferritin protein will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3774457